TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -32.61% | 14.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -32.61% | 14.17% | |||
| Cost of Revenue | -30.19% | -7.56% | |||
| Gross Profit | -32.98% | 18.46% | |||
| SG&A Expenses | 5.93% | -10.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.06% | -19.94% | |||
| Operating Income | -157.14% | 63.71% | |||
| Income Before Tax | 115.82% | 9.74% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | 115.78% | 9.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 115.78% | 9.79% | |||
| EBIT | -157.14% | 63.71% | |||
| EBITDA | -163.15% | 64.47% | |||
| EPS Basic | 114.12% | 78.28% | |||
| Normalized Basic EPS | -13.82% | 68.22% | |||
| EPS Diluted | 114.12% | 78.28% | |||
| Normalized Diluted EPS | -13.82% | 68.22% | |||
| Average Basic Shares Outstanding | 11.68% | 8.80% | |||
| Average Diluted Shares Outstanding | 11.68% | 8.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||